It is estimated that about 400,000 people in Poland suffer from rheumatoid arthritis (RA). Only a few epidemiological studies documenting the incidence of musculoskeletal disorders in the Polish population have been conducted. The medical literature mainly states that rheumatoid arthritis affects approximately 1% of the population and occurs 2-4 times more often in women than in men. RA is a disease that can develop at any age. In this group of diseases, indirect costs significantly exceed direct costs. Easier and more efficient access to rheumatology outpatient clinics would contribute to a quicker diagnosis of patients and, consequently, to reducing indirect costs of RA, and access to modern therapies would translate into a reduction of indirect costs related to rheumatoid arthritis. Results of studies conducted by other authors available in literature demonstrate that these diseases cause both an increased absence at work, i.e. missing days at work, and presenteeism, i.e. an increased ineffective presence at work due to ill-being. Indirect costs increase with increased disease activity. These costs can be significantly reduced through early diagnosis and introduction of effective treatment.

Indirect costs; Rheumatoid arthritis

E. Suresh, “Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know,” J R Soc Med, no. 97, pp. 421-424, 2004.

”Wczesna diagnostyka chorób reumatycznych- ocena obecnej sytuacji i rekomendacje zmian” [Early diagnosis of rheumatic diseases - assessment of the current situation and recommendations for changes], Brygida Kwiatkowska, Warsaw, 2014.

D. Scott, F. Wolfe and T. Huizinga, “Rheumatoid arthritis,” Lancet, no. 376, pp. 1094-1108, 2010.

“Postępy reumatologii klinicznej” [Advances in clinical rheumatology], Irena Zimmermann-Górska, Warsaw, 2014,

“Podstawy rehabilitacji dla studentów medycyny” [Basics of rehabilitation for medical students], Zdzisława Wrzosek, Janusz Bolanowski, Warsaw, 2011.

“Stanowisko Zespołu Ekspertów ds. Diagnostyki i Terapii Chorób Reumatycznych – sierpień 2006” [Position of the Team of Experts on Diagnosis and Therapy of Rheumatic Diseases - August 2006], Przegląd reumatologiczny, no. 4, pp. 3-5, 2006.

W. Tłustochowicz, “Postępy w diagnostyce i terapii chorób reumatycznych” [Advances in the diagnosis and therapy of rheumatic diseases], Przew Lek, no. 1, pp. 94-101, 2011.

Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: Results from the Norfolk Arthritis Register. Arthritis Care Res 2014.

Wiland P, Świerkot J, Maśliński W. Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów [Certolizumab pegol in the treatment of rheumatoid arthritis], Reumatologia 2011; 49: 253-263.

A. Filipowicz-Sosnowska, E. Stanisławska-Biernat and A. Zubrzycka-Sienkiewicz, “Reumatoidalne zapalenia stawów” [Rheumatoid arthritis], Reumatologia, no. 42 (1), pp. 3-16, 2004.

Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2013.

P. Scutellari and C. Orzincolo, “Rheumatoid arthritis: sequences,” Eur J Radiol, no. 27 (1), pp. 3138, 1998.

P. Scutellari and C. Orzincolo, “Rheumatoid arthritis: sequences,” Eur J Radiol, no. 27 (1), pp. 3138, 1998.

Escorpizo R, Bombardier C, Boonen A, et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007; 34: 13721380.

Mattke S, Balakrishnan A, Bergamo G, et al. A review of methods to measure health-related productivity loss. Am J Manag Care 2007; 13.

Huscher D, Mittendorf T, Hinüber U, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis 2015; 74: 738-745.

Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 2014.

Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology 2012.

F. Breedveld i J. Kalden, “Appropriate and effective management of rheumatoid arthritis,” Ann Rheum Dis, no. 63, pp. 627-633, 2004.

http://tradersarea.pl/miedzynarodowy-fundusz-walutowy-mfw/- International Monetary Fund